SLN
OTC MARKETS · Biotechnology
Silence Therapeutics PLC
$13.97
+0.39 (+2.87%)
Financial Highlights (FY 2026)
Revenue
10.49M
Net Income
-24,323,307
Gross Margin
37.8%
Profit Margin
-231.4%
Rev Growth
+315.5%
D/E Ratio
2.02
Income Statement
| FY 2026 | |
|---|---|
| Revenue | 10.49M |
| Gross Profit | 3.97M |
| Operating Income | -29,122,220 |
| Net Income | -24,323,307 |
| Gross Margin | 37.8% |
| Operating Margin | -277.7% |
| Profit Margin | -231.4% |
| Rev Growth | +315.5% |
Balance Sheet
| FY 2026 | |
|---|---|
| Total Debt | 214.60M |
| Total Equity | 106.20M |
| D/E Ratio | 2.02 |
Cash Flow
| FY 2026 | |
|---|---|
| EBITDA | -24,883,165 |
| Free Cash Flow | — |